Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company’s preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

90

Address:

Aeglea BioTherapeutics, Inc. 805 Las Cimas Parkway Suite 100 Austin TX 78746 United States

Website:

http://www.aeglea.com

Phone:

512-942-2935

Leave a comment

Your email address will not be published. Required fields are marked *